Evidence map›Paper›PMID 32057572›Full record

ArticleVaccine2020

CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine.

E N Gary, N Kathuria, G Makurumidze, A Curatola, A Ramamurthi, M E Bernui, D Myles, J Yan, P Pankhong, K Muthumani and 4 more

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

E N GaryThe Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
N KathuriaThe Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
G MakurumidzeThe Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, United States.
A CuratolaThe Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
A RamamurthiThe Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
M E BernuiThe Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States; The Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, United States.
D MylesThe Department of Pathology and Laboratory Medicine, The University of Pennsylvania, Philadelphia, PA, United States.
J YanInovio Pharmaceuticals, Blue Bell, PA, United States.
P PankhongThe Department of Pathology and Laboratory Medicine, The University of Pennsylvania, Philadelphia, PA, United States.
K MuthumaniThe Wistar Institute, Philadelphia, PA, United States.
E HaddadThe Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, United States.
L HumeauInovio Pharmaceuticals, Blue Bell, PA, United States.
D B WeinerThe Wistar Institute, Philadelphia, PA, United States.
M A KutzlerThe Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States; The Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, United States. Electronic address: mak98@drexel.edu.
Drexel University · USInovio Pharmaceuticals (United States) · USThe Wistar Institute · USUniversity of Pennsylvania · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
T Cell Functionality After DNA and Adjuvant VaccinationP01AI071739 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI MARX, PRESTON A · 2007 to 2013
$10.1M
Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
TNT: Targeting and Triggering Adjuvancy of DNA VaccinesF32AI054152 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KUTZLER, MICHELE AILEEN · 2003 to 2005
$139k
NCI NIH HHS T32 CA009171NIAID NIH HHS F32 AI054152NIAID NIH HHS P01 AI071739NIMH NIH HHS T32 MH079785
6 · The paper itself

Abstract

An effective prophylactic vaccine targeting HIV must induce a robust humoral response and must direct the bulk of this response to the mucosa-the primary site of HIV transmission. The chemokine, CCL28, is secreted by epithelial cells at mucosal surfaces and recruits' cells expressing its receptor CCR10. CCR10 is predominantly expressed by IgA + ASCs. We hypothesized that co-immunization with plasmid DNA encoding consensus envelope antigens with plasmid-encoded CCL28 would enhance anti-HIV IgA responses at mucosal surfaces. Indeed, animals receiving pCCL28 and pEnvA/C had significantly increased HIV-specific IgA in fecal extract. Surprisingly, CCL28 co-immunization induced a significant increase in anti-HIV IgG in the serum in mice compared to those receiving pEnvA/C alone. These robust antibody responses were not associated with changes in the frequency of germinal center B cells but depended upon the expression of CCR10, as these responses we abolished in CCR10-deficient animals. Finally, immunization with CCL28 led to increased frequencies in HIV-specific CCR10 + and CCR10 + IgA + B cells in the small intestine and Peyer's patches of vaccinated animals as compared to those receiving pEnvA/C alone. These data indicate that CCL28 administration can enhance antigen-specific humoral responses systemically and at mucosal surfaces.

Indexed as

Adjuvants, ImmunologicAIDS VaccinesAnimalsChemokines, CCenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesImmunity, MucosalImmunoglobulin AImmunoglobulin GMiceMucous MembraneReceptors, CCR10Vaccines, DNAAdjuvants, ImmunologicAIDS VaccinesCcr10 protein, mouseChemokines, CCenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesImmunoglobulin AImmunoglobulin GReceptors, CCR10Vaccines, DNACCL28/MECCCR10DNA vaccineIn vivo electroporationMucosal IgA antibody

Identifiers

PMID32057572
PMCPMC10681704
OpenAlexW3005882339

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.